Pacific Edge (NZE:PEB, ASX:PEB) said the Medicare coverage for its flagship Cxbladder test has been extended by two months to Thursday, April 24, according to a Monday filing with the New Zealand and Australian bourses.
Last Jan. 22, the cancer diagnostics company disclosed plans to seek a preliminary injunction in the US relating to the removal of Cxbladder test from the coverage of Medicare contractor, Novitas.
Pacific Edge's shares were up 7% in New Zealand and 10% in Australia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.